CY1113177T1 - Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων - Google Patents

Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων

Info

Publication number
CY1113177T1
CY1113177T1 CY20121100941T CY121100941T CY1113177T1 CY 1113177 T1 CY1113177 T1 CY 1113177T1 CY 20121100941 T CY20121100941 T CY 20121100941T CY 121100941 T CY121100941 T CY 121100941T CY 1113177 T1 CY1113177 T1 CY 1113177T1
Authority
CY
Cyprus
Prior art keywords
phenylamino
carboxylic acids
benzoxazol
medicines
preparation
Prior art date
Application number
CY20121100941T
Other languages
English (en)
Inventor
Elisabeth Defossa
Markus Follmann
Thomas Klabunde
Viktoria Drosou
Gerhard Hessler
Siegfried Stengelin
Guido Haschke
Andreas Herling
Stefan Bartoschek
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1113177T1 publication Critical patent/CY1113177T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε φαινυλαμινο-βενζοξαζολ-υποκατεστημένα καρβοξυλικά οξέα καθώς και στα φυσιολογικά ανεκτά άλατα τους. Η εφεύρεση αφορά σε ενώσεις του τύπου (I), όπου τα R1, R2, R6, R7, R8, R9, R10, m και Χ έχουν τις δεδομένες σημασίες, καθώς και στα φυσιολογικά ανεκτά άλατα τους. Οι ενώσεις ενδείκνυνται π.χ. για τη θεραπευτική αντιμετώπιση του διαβήτη.
CY20121100941T 2006-05-11 2012-10-12 Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων CY1113177T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP07724733A EP2024347B1 (de) 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
CY1113177T1 true CY1113177T1 (el) 2016-04-13

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100941T CY1113177T1 (el) 2006-05-11 2012-10-12 Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων

Country Status (31)

Country Link
US (2) US20090149519A1 (el)
EP (1) EP2024347B1 (el)
JP (1) JP2009536629A (el)
KR (1) KR20090006846A (el)
CN (1) CN101437805B (el)
AR (1) AR060990A1 (el)
AU (1) AU2007250213B2 (el)
BR (1) BRPI0711448A2 (el)
CA (1) CA2651660A1 (el)
CO (1) CO6241107A2 (el)
CY (1) CY1113177T1 (el)
DE (1) DE102006021878A1 (el)
DK (1) DK2024347T3 (el)
ES (1) ES2391203T3 (el)
HK (1) HK1131978A1 (el)
HR (1) HRP20120829T1 (el)
IL (1) IL195179A0 (el)
MA (1) MA30402B1 (el)
MX (1) MX2008014102A (el)
MY (1) MY148258A (el)
NO (1) NO20085068L (el)
NZ (1) NZ572692A (el)
PL (1) PL2024347T3 (el)
PT (1) PT2024347E (el)
RS (1) RS52450B (el)
RU (1) RU2434003C2 (el)
SI (1) SI2024347T1 (el)
TW (1) TW200812987A (el)
UY (1) UY30338A1 (el)
WO (1) WO2007131622A1 (el)
ZA (1) ZA200808490B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
WO2009145829A1 (en) * 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2020206036A1 (en) 2019-01-11 2021-08-05 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0664792B1 (en) * 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
ES2201452T3 (es) * 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima impdh.
EP1133484A2 (en) * 1998-07-23 2001-09-19 AstraZeneca AB Heterocyclic derivatives and their use as integrin inhibitors
DE60027700T2 (de) * 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
WO2002036553A2 (en) * 2000-11-04 2002-05-10 Aventis Pharma Limited Substituted alkanoic acids
IL156064A0 (en) * 2000-12-28 2003-12-23 Daiichi Seiyaku Co Vla-4 inhibitors
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
HK1131978A1 (en) 2010-02-12
JP2009536629A (ja) 2009-10-15
EP2024347B1 (de) 2012-08-01
US20090149519A1 (en) 2009-06-11
EP2024347A1 (de) 2009-02-18
IL195179A0 (en) 2009-08-03
PT2024347E (pt) 2012-10-09
NZ572692A (en) 2011-03-31
SI2024347T1 (sl) 2012-11-30
US20130303578A1 (en) 2013-11-14
NO20085068L (no) 2009-02-04
AR060990A1 (es) 2008-07-30
WO2007131622A1 (de) 2007-11-22
CA2651660A1 (en) 2007-11-22
CO6241107A2 (es) 2011-01-20
KR20090006846A (ko) 2009-01-15
AU2007250213A1 (en) 2007-11-22
CN101437805B (zh) 2012-05-30
RU2008148838A (ru) 2010-06-20
US8748465B2 (en) 2014-06-10
PL2024347T3 (pl) 2013-01-31
UY30338A1 (es) 2008-01-02
MA30402B1 (fr) 2009-05-04
DK2024347T3 (da) 2012-10-29
MY148258A (en) 2013-03-29
AU2007250213B2 (en) 2013-04-11
MX2008014102A (es) 2008-11-14
HRP20120829T1 (hr) 2012-11-30
ES2391203T3 (es) 2012-11-22
TW200812987A (en) 2008-03-16
RS52450B (en) 2013-02-28
CN101437805A (zh) 2009-05-20
DE102006021878A1 (de) 2007-11-15
BRPI0711448A2 (pt) 2011-11-08
ZA200808490B (en) 2009-10-28
RU2434003C2 (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
CY1113177T1 (el) Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
CY1122895T1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CY1112115T1 (el) Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου
CY1117038T1 (el) Υποκατεστημενες εναμινοκαρβονυλ ενωσεις
CY1119605T1 (el) Παραγωγα 5-αρυλο ή 5-ετεροαρυλο υποκατεστημενου 3-υδροξυπυριδιν-2-υλ-καρβονυλαμινο-αλκανοϊκου οξεος και αλατα αυτων καθως και παρασκευη τους απο τα αντιστοιχα παραγωγα 3-υδροξυ-πικολινικου οξεος
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
CY1110812T1 (el) Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CY1110318T1 (el) Παραγωγα φαινοξυοξικου οξεος
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
CY1117330T1 (el) Βενζοδιοξινυλ υποκατεστημενα παραγωγα ινδαζολιου
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
CY1111367T1 (el) Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
CY1115176T1 (el) Ρυθμιστες υποδοχεων τυπου toll
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
EA201170772A1 (ru) Органические соединения
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
EA201290416A1 (ru) Новые спиропиперидиновые соединения